Inspiremd Inc. · NASDAQ:NSPR
Inspiremd — Investor Presentation (April 2020)
27 slides from Inspiremd's investor presentation, Apr 3, 2020
Slide 1: Corporate Presentation April 2020
e ion. Corporate Presentation April 2020 _ aw ‘ained bolic tect ro S inspireMD
Slide 2: Disclaimer
mi DISCLAIMER Forward-looking Statements This presentation contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," “anticipates,” "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words.
Slide 3: About InspireMD
m™ About InspireMD MicroNet is a proprietary Zt S platform comprised of thin, 20- - . E > micron polyethylene InspireMD is a commercial-stage medical : : lyethyl device company focused on stroke G7 Ly - ferebhialate mes eabe designed to trap and maintain prevention in patients with carotidartery = 7
Slide 4: About InspireMD
mM About InspireMD Ticker NYSE AMER: | Price (A/0 4/1/20): $0.62 # of employees: 47 Shares outstanding (including tull conversion of preferred shares): 5.0 million Headquarters & manufacturing Market cap (inctuding full conversion of preferred shares): $3.0 million fa be v Fiscal year end: December
Slide 5: About InspireMD
About InspireMD Peripheral Treatment: PGuard™EPS US Neuro Treatment: References: 1. Musialek P et al. PARADIGM-Extend Prospective Academic Trial: Accumulating long-term evidence for MicroNet-covered stent safety and stroke prevention efficacy. ° Presentation at ESC Congress 2019, Paris, France, 31 A
Slide 6: Company Highlights
m Company Highlights Enabling a paradigm shift (CAS) in the treatment of carotid artery disease and stroke prevention CGuard™ EPS Breakthrough platform: Highly differentiated, with strong support from leading clinicians MicroNet™ technology that is elegantly simple, propriety and easily leveraged to
Slide 7: InspireMD 2.0
= InspireMD 2.0 Re-setting Awareness, Establishing Value, and Advancing Body of Evidence to Change The Standard of Care In late 2019, InspireMD: ™ Established new leadership _ Implemented focused commercial strategy in approved markets ™ Committed to a patient-first approach while being accountable
Slide 8: Billion Dollar Market Opportunity
mA Billion Dollar Market Opportunity Our MicroNet™-covered stents like CGuard™ could become the new gold standard * 2.2M diagnosed with carotid artery disease (CAD) WW carotid procedures today are Carotid procedures tomorrow could be primarily surgical: mostly minimally invasive with Coguard™ * 2017
Slide 9: Stroke is the Second Biggest Cause of Death Globally
m™i Stroke is the Second Biggest Cause of Death Globally An estimated 15 million people suffer from stroke annually’ * 6.2 million deaths? Top Two Causes of Death Globally (2016)® *5 million people left permanently disabled? * $34 billion associated with stroke management in the US alone? * ~85% of
Slide 10: The Problem: Risks with Existing Approaches to CAD
mi THE PROBLEM: Risks with Existing Approaches to CAD Surgery (CEA) and conventional Carotid Artery Stenting (CAS) both come with risks Carotid Endarterectomy (CEA) Carotid Artery Stenting (CAS) Risk of complications: Risk of complications: * Myocardial infarction risk? (heart attack) * Procedural a
Slide 11: The Problem: Risk of Embolism Following Conventional CAS
THE PROBLEM: Risk of Embolism Following Conventional CAS 90% occlusion of MRI of a pre-existing white Successful MRI reveals new multiple micro- the carotid matter infarction (obstruction) opening of the infarcts (obstructions) due to artery carotid artery liberation of embolic particles inspireMD C
Slide 12: The Problem: Risk of Embolism Following Conventional CAS
mi THE PROBLEM: Risk of Embolism Following Conventional CAS Plaque protrusion through stent struts occurs in up to 65% of conventional carotid stents,* resulting in embolus formation and cerebral embolization Area of blocked blood Bare stent flow in stroke victim Embolus . becomes Conventional stent
Slide 13: CGuard EPS Is Our Solution for Carotid Artery Stenting (CAS)
mi CGuard™ EPS Is Our Solution for Carotid Artery Stenting (CAS) Covered stent with the smallest pore size, permanently prevents the occurrence of plaque prolapse and thrombus facilitating natural endothelialization Much lower risk of flow TM CGuardsignt of blood to brain interuption MicroNet™ mesh
Slide 14: Our Solution: Proprietary MicroNet Technology
m™ OUR SOLUTION: Proprietary MicroNet™ Technology New mesh covered stent that offers superior plaque coverage when compared to conventional stent approaches MicroNet™: an Embolic Prevention System (EPS) for Ultimate Thrombus Protection Ultrathin flexible mesh sleeve, designed to expand seamlessly du
Slide 15: Carotid Solution: Our Well Studied Mesh-Covered Technology
Mi Carotid Solution: Our Well Studied Mesh-Covered Technology More than 1,600 patients in Clinical Publications and Studies Highly-caleific car Benno Insymptomatie at eyaeitel_ antes | (patients ating tig = . Clinical Resu ‘Analysis from the of the Caroth Embolie Pret dae HO! ® | pearrete ta ‘era Bo
Slide 16: Growth: From Alternative Stent to New Gold Standard
owth: From Alternative Stent to New Gold Standard Timeline YEAR STUDY PUBLICATION HIGHLIGHTS CGUARD’S STANDING {known & anticipated) PARADIGM EXTEND * _Large long-term study for all commers; CGuard study of long-term results aj CGuard demonstrates superiority to surgery OPTIMA * IVUS assessment afte
Slide 17: CGuard EPS Yields Superior Clinical Outcomes
mi CGuard™ EPS Yields Superior Clinical Outcomes When compared with Conventional Stents and Surgery (CEA), CGuard™ trends Superior 30 Day DSM (Death, Stroke, Myocardial Infarction) * CGuard™ has a superior profile versus 6.00% historical data on both conventional 520% carotid stents and surgery 5.00
Slide 18: Our Commercial Strategy
m™ Our Commercial Strategy Continued commercial Continue to support Continue to develop KOLs, focus on CGuard™ EPS investigator initiated broaden centers of carotid stents to CGuard™ EPS clinical data clinical studies excellence to multiple clinical disciplines Transition current users of Publish, p
Slide 19: We Are Currently Active in Over Markets
mi We Are Currently Active in Over 39 Markets (Dark Blue) * Over 90% of sales are indirect through a range of distributors * New markets under consideration / development include Japan, S Korea and China ¢ Discussions progressing with FDA regarding IDE; targeting initiation of US trial in 2021 teubj
Slide 20: Our Lead Product, CGuard - Advancing Rapidly
™ Our Lead Product, CGuard™- Advancing Rapidly CGuard™ has potential to ‘e) become the new standard-of- : 3 1 % 1 8 , O O O care for carotid indications Total protected stents *Achieved clinical milestones; growth of CGuard™ sold to date with neuroprotective vs other carotid portfolio in Q4 2019 art
Slide 21: Endovascular Procedures: Landscape and InspireMD Potential
mi Endovascular Procedures: Landscape and InspireMD Potential* Cerebral Aneurysms Coronary Artery Disease Thoracic/ Abdominal Aortic Aneurysms Peripheral Arterial Disease (PAD) *Management Estimate O = Surgical Market Potential Open to Endo Conversion: * CAROTID ARTERY DISEASE (ww) Procedures in 201
Slide 22: Positioned for Growth
iPositioned for Growth MARKET EXPANSION GLOBAL $ EXPANSION PRODUCT e EXPANSION INDICATION a EXPANSION a MARKET CONVERSION (CEA ¢ TO CAS) Penetration SHARE GROWTH IN e a Existing Endo Mkt with EXISITING CAS MARKET USANDASIA _‘MicroNet Coverage markets . Leverage CGuard in standard surgical vader indi
Slide 23: Our Advancement Roadmap / Milestones
Our Advancement Roadmap / Milestones Q 2022 and Beyond Expand Broad Global *Launch CGuard™ in U.S. & Japan Embolic Protection Indications * Expanded indications for MicroNet *Demonstrate Superiority of CGuard™ in CAS *Grow above market in those served *Launch CGuard™ in Brazil *Complete CGuard™ IDE
Slide 24: Our Robust Intellectual Property Portfolio
m™ Our Robust Intellectual Property Portfolio Proprietary platform technology supported by IP Patent Rights Allowed Pending USA 13 Rest of World 47 * InspireMD will continue to strengthen and broaden its patent protection globally to enable future pipeline products inspireMD Confidential [J 24
Slide 25: Our Business and Market Development
Mi Our Business and Market Development Strategic Targets for Merger or Acquisition Synergy > E—Ct LD > —C— > E—C—tsSZ | | — Boston, Cc | Medtronic Edwards " Peecdinnilleniil: Scientific 5 Abbott TERUMO BIOSENSORS eee ese Veleflex: Dvermanicx BAMRID Mefil 8 BMicrorort co csi SILKROAD» Minar Stevens n
Slide 26: Our Leadership
mi Our Leadership Mr. Slosman has over 30 years of experience in the medical device industry with focused leadership in commercialization and international market development in both public and privately held companies. He has had senior management roles in a variety of public and privately held com
Slide 27: Investor Contact
; INVESTOR CONTACT Scott Gordon President, CORE IR 516.222.2560 scottg@coreir.com NYSE AMERICAN (NSPR) inspireMD Sustained Embolic Protection.